Literature DB >> 9184262

Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity.

L T Kopeikina1, E F Kamper, V Koutsoukos, Y Bassiakos, I Stavridis.   

Abstract

The relationship between plasma fibrinogen, D-dimer (DD), t-PA and PAI-1 and their correlation with disease activity (DA) were studied in 45 patients with rheumatoid arthritis (RA) (group B) to further understand the implication of fibrinolysis in the pathophysiology of RA. The control group constituted 24 healthy subjects (group A). A Stoke index (SI) of DA was assigned to each patient. Patients were divided into two groups: C, minimal-mild DA (SI 1-7); D, moderate-severe DA (SI 8-17). Fibrinogen was elevated in RA correlating positively with SI and CRP. Hypercoagulability counteracted by reactive fibrinolysis was inferred from a 10-fold increase of DD in group B as compared to group A. The relatively lower levels of DD in group D compared to group C and their negative correlation with SI (r(s) = -0.49, p = 0.0006) indicate the tendency of fibrinolysis to decrease with the increase of DA. Significant elevation of t-PA and PAI-1 were found in group B compared to group A. While t-PA progressively decreased with the increase of DA (r(s) = -0.45, p = 0.0019), a positive relation of PAI-1 to DA was observed (r = 0.42, p = 0.0042). A 2-fold increase of PAI-1/t-PA molar ratio in group D compared to groups A and C as well as its positive correlation with SI (r(s) = 0.63, p = 0.0001) indicate the displacement of balance between t-PA and PAI-1 in favour of the inhibitor with the increase of DA in RA. The involvement of inflammatory mediators in PAI-1/t-PA imbalance was proposed from the relation of fibrinolytic abnormalities with the activity of systemic inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184262     DOI: 10.1007/BF02238960

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

Review 2.  Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions.

Authors:  D A Hart; M J Fritzler
Journal:  J Rheumatol       Date:  1989-09       Impact factor: 4.666

3.  Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.

Authors:  E F Kamper; L T Kopeikina; V Koutsoukos; J Stavridis
Journal:  J Rheumatol       Date:  1997-02       Impact factor: 4.666

4.  The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol.

Authors:  J J Belch; R Madhok; B McArdle; K McLaughlin; C Kluft; C D Forbes; R D Sturrock
Journal:  Q J Med       Date:  1986-01

5.  Increase of activated factor VIIA and haemostatic molecular markers in juvenile chronic arthritis.

Authors:  Y Inamo; S Pemberton; E G Tuddenham; P Woo
Journal:  Br J Rheumatol       Date:  1995-05

Review 6.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

7.  Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.

Authors:  V W van Hinsbergh; E A van den Berg; W Fiers; G Dooijewaard
Journal:  Blood       Date:  1990-05-15       Impact factor: 22.113

8.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

Authors:  P J Declerck; M C Alessi; M Verstreken; E K Kruithof; I Juhan-Vague; D Collen
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

9.  Physiological consequences of loss of plasminogen activator gene function in mice.

Authors:  P Carmeliet; L Schoonjans; L Kieckens; B Ream; J Degen; R Bronson; R De Vos; J J van den Oord; D Collen; R C Mulligan
Journal:  Nature       Date:  1994-03-31       Impact factor: 49.962

10.  Dynamic coronary fibrinolysis evaluation in patients with myocardial infarction and unstable angina by specific plasma fibrin degradation product determination.

Authors:  C Soria; J Soria; M Mirshahi; M Mirshahi; S Dunnica; C Boucheix; R Beaufils; R Slama; J P Caen
Journal:  Thromb Res       Date:  1987-02-15       Impact factor: 3.944

View more
  4 in total

1.  Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease.

Authors:  Jakub Kwieciński; Elisabet Josefsson; Tao Jin
Journal:  Inflamm Res       Date:  2011-07-24       Impact factor: 4.575

2.  Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors.

Authors:  Theodoros Dimitroulas; Karen M J Douglas; Vasileios F Panoulas; Tracey Toms; Jacqueline P Smith; Gareth J Treharne; Peter Nightingale; James Hodson; George D Kitas
Journal:  Clin Rheumatol       Date:  2013-05-15       Impact factor: 2.980

3.  Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade.

Authors:  Konstantinos Makrilakis; Kalliopi Fragiadaki; Jacqueline Smith; Petros P Sfikakis; George D Kitas
Journal:  Clin Rheumatol       Date:  2014-06-10       Impact factor: 2.980

4.  Accelerated Spatial Fibrin Growth and Impaired Contraction of Blood Clots in Patients with Rheumatoid Arthritis.

Authors:  Alina D Peshkova; Tatiana A Evdokimova; Timur B Sibgatullin; Fazoil I Ataullakhanov; Rustem I Litvinov; John W Weisel
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.